Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.49 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.30 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6806018 | 0.91 | TUBB1 (0.46) | TUBB1AAK1GAAMEN1KMT2A | |
| SCHEMBL6805738 | 0.90 | TUBB1 (0.60) | TUBB1AAK1KDM4EALDH1A1 | |
| SCHEMBL6803333 | 0.89 | TUBB1 (0.59) | TUBB1 | |
| SCHEMBL6670282 | 0.88 | TUBB1 (0.62) | TUBB1KDM4EALDH1A1GAAHPGD | |
| SCHEMBL6671660 | 0.86 | TUBB1 (0.44) | TUBB1GAA | |
| SCHEMBL6675014 | 0.86 | TUBB1 (0.44) | TUBB1GAA | |
| SCHEMBL29511164 | 0.84 | TUBB1 (0.49) | TUBB1 | |
| SCHEMBL22069860 | 0.84 | TUBB1 (0.49) | TUBB1 | |
| SCHEMBL58263 | 0.84 | TUBB1 (0.49) | TUBB1 | |
| SCHEMBL13660105 | 0.84 | TUBB1 (0.49) | TUBB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040121965-A1 | Method of treating resistant tumors | WYETH HOLDINGS CORPORATION (US) | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040121965-A1 | Method of treating resistant tumors | SLC11A2, VHL, REN | TUBB1 199/4885AAK1 4223/4885KDM4E 2744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.